40589-V08H4 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 98
    Sino Biological sars cov 2 2019 ncov spike s1 his recombinant protein hplc verified covid 19 spike s1 research
    Sars Cov 2 2019 Ncov Spike S1 His Recombinant Protein Hplc Verified Covid 19 Spike S1 Research, supplied by Sino Biological, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 2019 ncov spike s1 his recombinant protein hplc verified covid 19 spike s1 research/product/Sino Biological
    Average 98 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 2019 ncov spike s1 his recombinant protein hplc verified covid 19 spike s1 research - by Bioz Stars, 2021-04
    98/100 stars
      Buy from Supplier

    97
    Sino Biological sars cov 2 2019 ncov nucleocapsid his recombinant protein covid 19 nucleocapsid research
    Sars Cov 2 2019 Ncov Nucleocapsid His Recombinant Protein Covid 19 Nucleocapsid Research, supplied by Sino Biological, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 2019 ncov nucleocapsid his recombinant protein covid 19 nucleocapsid research/product/Sino Biological
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 2019 ncov nucleocapsid his recombinant protein covid 19 nucleocapsid research - by Bioz Stars, 2021-04
    97/100 stars
      Buy from Supplier

    86
    Sino Biological sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research
    Sars Cov 2 2019 Ncov Spike Rbd His Recombinant Protein Covid 19 Spike Rbd Research, supplied by Sino Biological, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research/product/Sino Biological
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research - by Bioz Stars, 2021-04
    86/100 stars
      Buy from Supplier

    86
    Sino Biological sars cov 2 2019 ncov spike s1 s2 ecd his recombinant protein covid 19 spike research
    T cell epitope mapping after INO-4800 administration to BALB/c mice. Splenocytes were stimulated for 20 h with <t>SARS-CoV-2</t> peptide matrix pools. a T cell responses following stimulation with matrix mapping SARS-CoV-2 peptide pools. Bars represent the mean + SD of five mice. b Map of the SARS-CoV-2 Spike protein and identification of immunodominant peptides in BALB/c mice. A known immunodominant SARS-CoV HLA-A2 epitope is included for comparison.
    Sars Cov 2 2019 Ncov Spike S1 S2 Ecd His Recombinant Protein Covid 19 Spike Research, supplied by Sino Biological, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 2019 ncov spike s1 s2 ecd his recombinant protein covid 19 spike research/product/Sino Biological
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 2019 ncov spike s1 s2 ecd his recombinant protein covid 19 spike research - by Bioz Stars, 2021-04
    86/100 stars
      Buy from Supplier

    Image Search Results


    T cell epitope mapping after INO-4800 administration to BALB/c mice. Splenocytes were stimulated for 20 h with SARS-CoV-2 peptide matrix pools. a T cell responses following stimulation with matrix mapping SARS-CoV-2 peptide pools. Bars represent the mean + SD of five mice. b Map of the SARS-CoV-2 Spike protein and identification of immunodominant peptides in BALB/c mice. A known immunodominant SARS-CoV HLA-A2 epitope is included for comparison.

    Journal: Nature Communications

    Article Title: Immunogenicity of a DNA vaccine candidate for COVID-19

    doi: 10.1038/s41467-020-16505-0

    Figure Lengend Snippet: T cell epitope mapping after INO-4800 administration to BALB/c mice. Splenocytes were stimulated for 20 h with SARS-CoV-2 peptide matrix pools. a T cell responses following stimulation with matrix mapping SARS-CoV-2 peptide pools. Bars represent the mean + SD of five mice. b Map of the SARS-CoV-2 Spike protein and identification of immunodominant peptides in BALB/c mice. A known immunodominant SARS-CoV HLA-A2 epitope is included for comparison.

    Article Snippet: Binding antigens tested included, SARS-CoV-2 antigens: S1 spike protein (Sino Biological 40591-V08H), S1 + S2 ECD spike protein (Sino Biological 40589-V08B1), RBD (University of Texas, at Austin (McLellan Lab.)); SARS-COV antigens: Spike S1 protein (Sino Biological 40150-V08B1), S (1-1190) (Immune Tech IT-002-001P) and Spike C-terminal (Meridian Life Science R18572).

    Techniques: Mouse Assay

    Humoral responses to SARS-CoV-2 in Hartley guinea pigs after a single dose of INO-4800. Hartley guinea pigs were immunized on Day 0 with 100 µg INO-4800 or pVAX-empty vector as described in the methods. a SARS-CoV-2 S protein antigen binding of IgG in serial serum dilutions at day 0 and 14. Data shown represent mean OD450 nm values (mean + SD) for the five guinea pigs. b Serum IgG binding titers (mean ± SD) to SARS-CoV-2 S protein at day 14. Values depicted are mean ± SD. P values determined by Mann–Whitney test.

    Journal: Nature Communications

    Article Title: Immunogenicity of a DNA vaccine candidate for COVID-19

    doi: 10.1038/s41467-020-16505-0

    Figure Lengend Snippet: Humoral responses to SARS-CoV-2 in Hartley guinea pigs after a single dose of INO-4800. Hartley guinea pigs were immunized on Day 0 with 100 µg INO-4800 or pVAX-empty vector as described in the methods. a SARS-CoV-2 S protein antigen binding of IgG in serial serum dilutions at day 0 and 14. Data shown represent mean OD450 nm values (mean + SD) for the five guinea pigs. b Serum IgG binding titers (mean ± SD) to SARS-CoV-2 S protein at day 14. Values depicted are mean ± SD. P values determined by Mann–Whitney test.

    Article Snippet: Binding antigens tested included, SARS-CoV-2 antigens: S1 spike protein (Sino Biological 40591-V08H), S1 + S2 ECD spike protein (Sino Biological 40589-V08B1), RBD (University of Texas, at Austin (McLellan Lab.)); SARS-COV antigens: Spike S1 protein (Sino Biological 40150-V08B1), S (1-1190) (Immune Tech IT-002-001P) and Spike C-terminal (Meridian Life Science R18572).

    Techniques: Plasmid Preparation, Binding Assay, MANN-WHITNEY

    Induction of T cell responses in BALB/c mice post-administration of INO-4800. BALB/c mice ( n = 5/group) were immunized with 2.5 or 10 µg INO-4800. T cell responses were analyzed in the animals on days 4, 7, 10 for plots a b, and day 14 for plot c. T cell responses were measured by IFN-γ ELISpot in splenocytes stimulated for 20h with overlapping peptide pools spanning the SARS-CoV-2 ( a ), SARS-CoV ( b ), or MERS-CoV ( c ) Spike proteins. Bars represent the mean + SD. Data from individual mice is shown in Supplementary Data 2 .

    Journal: Nature Communications

    Article Title: Immunogenicity of a DNA vaccine candidate for COVID-19

    doi: 10.1038/s41467-020-16505-0

    Figure Lengend Snippet: Induction of T cell responses in BALB/c mice post-administration of INO-4800. BALB/c mice ( n = 5/group) were immunized with 2.5 or 10 µg INO-4800. T cell responses were analyzed in the animals on days 4, 7, 10 for plots a b, and day 14 for plot c. T cell responses were measured by IFN-γ ELISpot in splenocytes stimulated for 20h with overlapping peptide pools spanning the SARS-CoV-2 ( a ), SARS-CoV ( b ), or MERS-CoV ( c ) Spike proteins. Bars represent the mean + SD. Data from individual mice is shown in Supplementary Data 2 .

    Article Snippet: Binding antigens tested included, SARS-CoV-2 antigens: S1 spike protein (Sino Biological 40591-V08H), S1 + S2 ECD spike protein (Sino Biological 40589-V08B1), RBD (University of Texas, at Austin (McLellan Lab.)); SARS-COV antigens: Spike S1 protein (Sino Biological 40150-V08B1), S (1-1190) (Immune Tech IT-002-001P) and Spike C-terminal (Meridian Life Science R18572).

    Techniques: Mouse Assay, Enzyme-linked Immunospot

    INO-4800 immunized mouse and guinea pig sera compete with ACE2 receptor for SARS-CoV-2 Spike protein binding. a Soluble ACE2 receptor binds to CoV-2 full-length spike with an EC 50 of 0.025 µg/ml. b Purified serum IgG from BALB/c mice ( n of 5 per group) after second immunization with INO-4800 yields significant competition against ACE2 receptor. Serum IgG samples from the animals were run in triplicate. c IgGs purified from n = 5 mice day 7 post second immunization with INO-4800 show significant competition against ACE2 receptor binding to SARS-CoV-2 S 1 + 2 protein. The soluble ACE2 concentration for the competition assay is ~0.1 µg ml −1 . Bars represent the mean and standard deviation of AUC for curves displayed in Supplementary Fig. 1 . d Hartley guinea pigs were immunized on Day 0 and 14 with 100 µg INO-4800 or pVAX-empty vector as described in the methods. Day 28 collected sera (diluted 1:20) was added SARS-CoV-2 coated wells prior to the addition of serial dilutions of ACE2 protein. Detection of ACE2 binding to SARS-CoV-2 S protein was measured. Sera collected from 5 INO-4800-treated and 3 pVAX-treated animals were used in this experiment. e Serial dilutions of guinea pig sera collected on day 21 were added to SARS-CoV-2 coated wells prior to the addition of ACE2 protein. Detection of ACE2 binding to SARS-CoV-2 S protein was measured. Sera collected from 4 INO-4800-treated and 5 pVAX-treated guinea pigs were used in this experiment.

    Journal: Nature Communications

    Article Title: Immunogenicity of a DNA vaccine candidate for COVID-19

    doi: 10.1038/s41467-020-16505-0

    Figure Lengend Snippet: INO-4800 immunized mouse and guinea pig sera compete with ACE2 receptor for SARS-CoV-2 Spike protein binding. a Soluble ACE2 receptor binds to CoV-2 full-length spike with an EC 50 of 0.025 µg/ml. b Purified serum IgG from BALB/c mice ( n of 5 per group) after second immunization with INO-4800 yields significant competition against ACE2 receptor. Serum IgG samples from the animals were run in triplicate. c IgGs purified from n = 5 mice day 7 post second immunization with INO-4800 show significant competition against ACE2 receptor binding to SARS-CoV-2 S 1 + 2 protein. The soluble ACE2 concentration for the competition assay is ~0.1 µg ml −1 . Bars represent the mean and standard deviation of AUC for curves displayed in Supplementary Fig. 1 . d Hartley guinea pigs were immunized on Day 0 and 14 with 100 µg INO-4800 or pVAX-empty vector as described in the methods. Day 28 collected sera (diluted 1:20) was added SARS-CoV-2 coated wells prior to the addition of serial dilutions of ACE2 protein. Detection of ACE2 binding to SARS-CoV-2 S protein was measured. Sera collected from 5 INO-4800-treated and 3 pVAX-treated animals were used in this experiment. e Serial dilutions of guinea pig sera collected on day 21 were added to SARS-CoV-2 coated wells prior to the addition of ACE2 protein. Detection of ACE2 binding to SARS-CoV-2 S protein was measured. Sera collected from 4 INO-4800-treated and 5 pVAX-treated guinea pigs were used in this experiment.

    Article Snippet: Binding antigens tested included, SARS-CoV-2 antigens: S1 spike protein (Sino Biological 40591-V08H), S1 + S2 ECD spike protein (Sino Biological 40589-V08B1), RBD (University of Texas, at Austin (McLellan Lab.)); SARS-COV antigens: Spike S1 protein (Sino Biological 40150-V08B1), S (1-1190) (Immune Tech IT-002-001P) and Spike C-terminal (Meridian Life Science R18572).

    Techniques: Protein Binding, Purification, Mouse Assay, Binding Assay, Concentration Assay, Competitive Binding Assay, Standard Deviation, Plasmid Preparation

    Detection of SARS-CoV-2 S protein-reactive antibodies in the BAL of INO-4800 immunized animals. BALB/c mice (n of 5 per group) were immunized on days 0 and 14 with INO-4800 or pVAX and BAL collected at day 21 ( a , b ). Hartley guinea pigs ( n of 5 per group) were immunized on days 0, 14 and 21 with INO-4800 or pVAX and BAL collected at day 42 ( c , d ). Bronchoalveolar lavage fluid was assayed in duplicate for SARS-CoV-2 Spike protein-specific IgG antibodies by ELISA. Data are presented as endpoint titers ( a , c ), and BAL dilution curves with raw OD 450 nm values ( b , d ). a , c Bars represent the average of each group and error bars the standard deviation. ** p

    Journal: Nature Communications

    Article Title: Immunogenicity of a DNA vaccine candidate for COVID-19

    doi: 10.1038/s41467-020-16505-0

    Figure Lengend Snippet: Detection of SARS-CoV-2 S protein-reactive antibodies in the BAL of INO-4800 immunized animals. BALB/c mice (n of 5 per group) were immunized on days 0 and 14 with INO-4800 or pVAX and BAL collected at day 21 ( a , b ). Hartley guinea pigs ( n of 5 per group) were immunized on days 0, 14 and 21 with INO-4800 or pVAX and BAL collected at day 42 ( c , d ). Bronchoalveolar lavage fluid was assayed in duplicate for SARS-CoV-2 Spike protein-specific IgG antibodies by ELISA. Data are presented as endpoint titers ( a , c ), and BAL dilution curves with raw OD 450 nm values ( b , d ). a , c Bars represent the average of each group and error bars the standard deviation. ** p

    Article Snippet: Binding antigens tested included, SARS-CoV-2 antigens: S1 spike protein (Sino Biological 40591-V08H), S1 + S2 ECD spike protein (Sino Biological 40589-V08B1), RBD (University of Texas, at Austin (McLellan Lab.)); SARS-COV antigens: Spike S1 protein (Sino Biological 40150-V08B1), S (1-1190) (Immune Tech IT-002-001P) and Spike C-terminal (Meridian Life Science R18572).

    Techniques: Mouse Assay, Enzyme-linked Immunosorbent Assay, Standard Deviation

    Comparison of SARS-CoV-2, SARS-CoV and MERS-CoV spike glycoproteins. a Amino acid alignment of coronavirus spike proteins including 11 SARS-CoV-2 sequences with mutations (GISAID). Gray bars indicates identical amino acids and colored bars represent mutations relative to Wuhan-Hu-1. RBD, Cleavage Site, Fusion Peptide and Transmembrane domains are indicated in red. b Structural models for SARS-CoV-2, SARS and MERS spike glycoproteins with one chain represented as cartoon and two chains represented as surface. RBD of SARS-CoV-2 is colored yellow.

    Journal: Nature Communications

    Article Title: Immunogenicity of a DNA vaccine candidate for COVID-19

    doi: 10.1038/s41467-020-16505-0

    Figure Lengend Snippet: Comparison of SARS-CoV-2, SARS-CoV and MERS-CoV spike glycoproteins. a Amino acid alignment of coronavirus spike proteins including 11 SARS-CoV-2 sequences with mutations (GISAID). Gray bars indicates identical amino acids and colored bars represent mutations relative to Wuhan-Hu-1. RBD, Cleavage Site, Fusion Peptide and Transmembrane domains are indicated in red. b Structural models for SARS-CoV-2, SARS and MERS spike glycoproteins with one chain represented as cartoon and two chains represented as surface. RBD of SARS-CoV-2 is colored yellow.

    Article Snippet: Binding antigens tested included, SARS-CoV-2 antigens: S1 spike protein (Sino Biological 40591-V08H), S1 + S2 ECD spike protein (Sino Biological 40589-V08B1), RBD (University of Texas, at Austin (McLellan Lab.)); SARS-COV antigens: Spike S1 protein (Sino Biological 40150-V08B1), S (1-1190) (Immune Tech IT-002-001P) and Spike C-terminal (Meridian Life Science R18572).

    Techniques:

    Design and expression of COVID-19 synthetic DNA vaccine constructs. a Schematic diagram of COVID-19 synthetic DNA vaccine constructs, pGX9501 (matched) and pGX9503 (outlier (OL)) containing the IgE leader sequence and SARS-CoV-2 spike protein insert. b RT-PCR assay of RNA extracts from COS-7 cells transfected in duplicate with pGX9501 and pGX9503. Extracted RNA was analyzed by RT-PCR using PCR assays designed for each target and for COS-7 β-Actin mRNA, used as an internal expression normalization gene. Delta C T (∆ C T ) was calculated as the C T of the target minus the C T of β-Actin for each transfection concentration and is plotted against the log of the mass of pDNA transfected (Plotted as mean ± SD). c Analysis of in vitro expression of Spike protein after transfection of 293T cells with pGX9501, pGX9503 or MOCK plasmid by Western blot. 293T cell lysates were resolved on a gel and probed with a polyclonal anti-SARS Spike Protein. Blots were stripped then probed with an anti-β-actin loading control. d In vitro immunofluorescent staining of 293T cells transfected with 3 µg/well of pGX9501, pGX9503 or pVax (empty control vector). Expression of Spike protein was measured with polyclonal anti-SARS Spike Protein IgG and anti-IgG secondary (green). Cell nuclei were counterstained with DAPI (blue). Images were captured using ImageXpress Pico automated cell imaging system. Scale bars are 80.15 µm (left), 66.8 µm (middle) and 77.31 µm (right).

    Journal: Nature Communications

    Article Title: Immunogenicity of a DNA vaccine candidate for COVID-19

    doi: 10.1038/s41467-020-16505-0

    Figure Lengend Snippet: Design and expression of COVID-19 synthetic DNA vaccine constructs. a Schematic diagram of COVID-19 synthetic DNA vaccine constructs, pGX9501 (matched) and pGX9503 (outlier (OL)) containing the IgE leader sequence and SARS-CoV-2 spike protein insert. b RT-PCR assay of RNA extracts from COS-7 cells transfected in duplicate with pGX9501 and pGX9503. Extracted RNA was analyzed by RT-PCR using PCR assays designed for each target and for COS-7 β-Actin mRNA, used as an internal expression normalization gene. Delta C T (∆ C T ) was calculated as the C T of the target minus the C T of β-Actin for each transfection concentration and is plotted against the log of the mass of pDNA transfected (Plotted as mean ± SD). c Analysis of in vitro expression of Spike protein after transfection of 293T cells with pGX9501, pGX9503 or MOCK plasmid by Western blot. 293T cell lysates were resolved on a gel and probed with a polyclonal anti-SARS Spike Protein. Blots were stripped then probed with an anti-β-actin loading control. d In vitro immunofluorescent staining of 293T cells transfected with 3 µg/well of pGX9501, pGX9503 or pVax (empty control vector). Expression of Spike protein was measured with polyclonal anti-SARS Spike Protein IgG and anti-IgG secondary (green). Cell nuclei were counterstained with DAPI (blue). Images were captured using ImageXpress Pico automated cell imaging system. Scale bars are 80.15 µm (left), 66.8 µm (middle) and 77.31 µm (right).

    Article Snippet: Binding antigens tested included, SARS-CoV-2 antigens: S1 spike protein (Sino Biological 40591-V08H), S1 + S2 ECD spike protein (Sino Biological 40589-V08B1), RBD (University of Texas, at Austin (McLellan Lab.)); SARS-COV antigens: Spike S1 protein (Sino Biological 40150-V08B1), S (1-1190) (Immune Tech IT-002-001P) and Spike C-terminal (Meridian Life Science R18572).

    Techniques: Expressing, Construct, Sequencing, Reverse Transcription Polymerase Chain Reaction, Transfection, Polymerase Chain Reaction, Concentration Assay, In Vitro, Plasmid Preparation, Western Blot, Staining, Imaging

    Neutralizing antibody responses after immunization of INO-4800. BALB/c mice ( n of 5 per group) were immunized twice on days 0 and 14 with 10 µg of INO-4800. Sera was collected on day 7 post-second immunization and serial dilutions were incubated with a pseudovirus displaying the SARS-CoV-2 Spike and co-incubated with ACE2–293T cells. a Neutralization ID50 (mean ± SD) in naïve and INO-4800 immunized mice and b relative luminescence units (RLU) for sera from naive mice (green) and mice vaccinated with INO-4800 (red) as described in “Methods”.

    Journal: Nature Communications

    Article Title: Immunogenicity of a DNA vaccine candidate for COVID-19

    doi: 10.1038/s41467-020-16505-0

    Figure Lengend Snippet: Neutralizing antibody responses after immunization of INO-4800. BALB/c mice ( n of 5 per group) were immunized twice on days 0 and 14 with 10 µg of INO-4800. Sera was collected on day 7 post-second immunization and serial dilutions were incubated with a pseudovirus displaying the SARS-CoV-2 Spike and co-incubated with ACE2–293T cells. a Neutralization ID50 (mean ± SD) in naïve and INO-4800 immunized mice and b relative luminescence units (RLU) for sera from naive mice (green) and mice vaccinated with INO-4800 (red) as described in “Methods”.

    Article Snippet: Binding antigens tested included, SARS-CoV-2 antigens: S1 spike protein (Sino Biological 40591-V08H), S1 + S2 ECD spike protein (Sino Biological 40589-V08B1), RBD (University of Texas, at Austin (McLellan Lab.)); SARS-COV antigens: Spike S1 protein (Sino Biological 40150-V08B1), S (1-1190) (Immune Tech IT-002-001P) and Spike C-terminal (Meridian Life Science R18572).

    Techniques: Mouse Assay, Incubation, Neutralization

    Humoral responses to SARS-CoV-2 and SARS-CoV antigens in BALB/c mice after a single dose of INO-4800. BALB/c mice were immunized on day 0 with indicated doses of INO-4800 or pVAX-empty vector as described in the methods. a Protein antigen binding of IgG at 1:50 and 1:250 serum dilutions from mice at day 14 immunized with 25 µg of INO-4800 or pVAX. Data shown represent mean OD450 nm values (mean + SD) for each group of 3 mice. b SARS-CoV-2 S1 + 2 or c SARS-CoV-2 RBD protein antigen binding of IgG in serial serum dilutions from mice at day 14. Data shown represent mean OD450 nm values (mean + SD) for each group of eight mice ( b , c ) and five mice ( d , e ). Serum IgG binding endpoint titers to ( c ) SARS-CoV-2 S1 + 2 and ( e ) SARS-CoV-2 RBD protein. Data representative of two independent experiments. Values depicted are mean +/− SD. P values determined by Mann–Whitney test.

    Journal: Nature Communications

    Article Title: Immunogenicity of a DNA vaccine candidate for COVID-19

    doi: 10.1038/s41467-020-16505-0

    Figure Lengend Snippet: Humoral responses to SARS-CoV-2 and SARS-CoV antigens in BALB/c mice after a single dose of INO-4800. BALB/c mice were immunized on day 0 with indicated doses of INO-4800 or pVAX-empty vector as described in the methods. a Protein antigen binding of IgG at 1:50 and 1:250 serum dilutions from mice at day 14 immunized with 25 µg of INO-4800 or pVAX. Data shown represent mean OD450 nm values (mean + SD) for each group of 3 mice. b SARS-CoV-2 S1 + 2 or c SARS-CoV-2 RBD protein antigen binding of IgG in serial serum dilutions from mice at day 14. Data shown represent mean OD450 nm values (mean + SD) for each group of eight mice ( b , c ) and five mice ( d , e ). Serum IgG binding endpoint titers to ( c ) SARS-CoV-2 S1 + 2 and ( e ) SARS-CoV-2 RBD protein. Data representative of two independent experiments. Values depicted are mean +/− SD. P values determined by Mann–Whitney test.

    Article Snippet: Binding antigens tested included, SARS-CoV-2 antigens: S1 spike protein (Sino Biological 40591-V08H), S1 + S2 ECD spike protein (Sino Biological 40589-V08B1), RBD (University of Texas, at Austin (McLellan Lab.)); SARS-COV antigens: Spike S1 protein (Sino Biological 40150-V08B1), S (1-1190) (Immune Tech IT-002-001P) and Spike C-terminal (Meridian Life Science R18572).

    Techniques: Mouse Assay, Plasmid Preparation, Binding Assay, MANN-WHITNEY